New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington's ...

Emil Kraepelin formulated the initial nosology of Alzheimer's disease in the first decade of the 20th century. Nowadays, clinical and pathological presentations (including those associated with ...

Results: Twenty patients (6.4%) had HER2-positive disease by immunohistochemistry and FISH. Only 7 (32%) patients (median age, 56 years; range, 48-68 years) met eligibility criteria; they had ...

The push to regard addiction as a disease is well-intentioned—driven by a desire to lessen stigma—but fails to account for the many facets and facts of the condition. Worse, it robs sufferers ...

All decisions on therapeutic or diagnostic procedures, treatments, disease management, timing of visits, or resource utilization will follow the investigator’s usual clinical practice (Figure 1). The ...

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...

Objectives Coeliac disease (CD) is a complex autoimmune disorder with known ... The objective of the present study was to determine the prevalence of positive CD serology in a population of Canadian ...

Respiratory tract diseases are illnesses that affect components of the respiratory system, including the nasal passages, the bronchi and the lungs. They range from acute infections, such as ...

Acute and chronic conditions typically differ in how they develop and how long they last. Broadly speaking, acute conditions occur suddenly, have immediate or rapidly developing symptoms, and are ...

This agent is being evaluated in PROSTACT GLOBAL, a phase 3 trial of standard of care therapy +/- 177 Lu-J591in ARPI-pre-treated mCRPC patients with PSMA-positive disease. The next ‘frontier’ of ...